MethylGene Inc.
Saint-Laurent, QC
Company Overview
MethylGene is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics in cancer and infectious diseases. We intend to exploit our HDAC inhibitor technology in other diseases, such as diabetes, inflammation, fungal infections and neurodegenerative disorders. Two cancer product candidates are currently in clinical trials: MGCD0103, partnered with Pharmion Corporation and Taiho Pharmaceutical Co., Ltd., and MG98, partnered with MGI Pharma, Inc. MethylGene has an exclusive license agreement with Merck & Co. for the development and commercialization of small molecule beta-lactamase inhibitors to overcome antibiotic resistance. MethylGene has partnered its non-oncology HDAC program for neurodegenerative diseases with EnVivo Pharmaceuticals. MethylGene has a portfolio of preclinical programs for its multi-targeted kinase and histone deacetylase (HDAC) inhibitors for both oncology and non-oncology indications, and continues to seek partnering opportunities in these areas.
MethylGene has received $41.9 million of investment and funding from Venture Capitalists, including a $4.8 million award from Technology Partnerships Canada. The company has also raised US$17.2 million in equity and upfront payments from their partners.
Company Information
Physical Address
200-7220 Frederick-Banting St
Saint-Laurent, QC H4S 2A1
CA
Mailing Address
200-7220 Frederick-Banting St
Saint-Laurent, QC H4S 2A1
CA
Additional Details
Legal Name: MethylGene Inc.
Number of Employees: 104
CA
MethylGene is a chemistry-driven company with broad in-house expertise in a number of key areas in drug discovery and development, including, medicinal chemistry, combinatorial chemistry, analytical chemistry, bioanalytical chemistry, enzymology, functional genomics and in vivo pharmacology.
Contacts
Donald F. Corcoran
Title: President & CEO
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
Jeffrey M. Besterman
Title: Executive Vice President & CSO
Area of Responsibility: Administrative Services, Research/Development/Engineering
Phone: Show phone
Fax: Show fax
Email: Show email
Services
- Pharmaceutical Products
Products
- Mgcd0103 Hdac Inhibitor In Clinical Trials For Oncology
NAICS Categories
- 325410 Pharmaceutical and Medicine Manufacturing
- 541380 Testing Laboratories
- 541710 Research and Development in the Physical, Engineering and Life Sciences
Additional Information
325410, 541380, 541710
Japan, United Kingdom, United States